NCT02060188 2025-11-06
CheckMate142
Bristol-Myers Squibb
Phase 2 Completed
Clinical Trials
8 trialsNCT04941287 2025-05-23
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06813079 2025-02-18
Using Tumor Models to Determine Treatments
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT02291289 2024-05-06
MODUL
Hoffmann-La Roche
Phase 2 Completed
NCT03201458 2024-04-05
Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT04591431 2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2 Unknown
NCT03340558 2018-10-09
ATELIER
Duke University
Phase 2 Withdrawn